Brought to you by 
Alzheon starts operations with Alzheimer’s IP from Bellus Health
03 Apr 2018
Executive Summary
Canadian biotech Bellus Health Inc. granted Alzheon Inc. (memory and aging diseases) exclusive worldwide rights to its Phase I Alzheimer’s drug candidate ALZ801 (previously known as BLU8499 and NRM8499); a set of tramiprosate analogs; and a drug development platform of chemotypes and clinical and biomarker datasets that could yield new compounds, including prodrugs of existing molecules that have gone through extensive efficacy testing, for neurodegenerative diseases.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alzheon starts operations with Alzheimer’s IP from Bellus Health
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice